Which second-generation antipsychotic is FDA-approved for reducing the risk of suicide?

Clozapine is the only second-generation antipsychotic that has received FDA approval specifically for reducing the risk of suicide in individuals with treatment-resistant schizophrenia. This approval is based on clinical evidence showing that clozapine effectively decreases suicidal behavior compared to other antipsychotics, making it a vital option in managing patients at high risk for suicide.

Clozapine's unique pharmacological profile allows it to address both the positive and negative symptoms of schizophrenia, as well as agitation, which can contribute to suicidal ideation. Its use is typically reserved for patients who do not respond adequately to other antipsychotic medications, underscoring its importance for this specific population.

In contrast, the other antipsychotics listed do not have the same specific FDA indication for suicide risk reduction. They may help manage symptoms of schizophrenia or related mood disorders, but they do not have the same strong evidence base for suicide prevention as clozapine does. Therefore, while they play significant roles in psychiatric treatment, they lack the specific designation for reducing suicide risk that clozapine possesses.